186 related articles for article (PubMed ID: 28303513)
1. Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms.
Leoncini E; Boffetta P; Shafir M; Aleksovska K; Boccia S; Rindi G
Endocrine; 2017 Nov; 58(2):368-379. PubMed ID: 28303513
[TBL] [Abstract][Full Text] [Related]
2. Incidence and survival trends for gastric neuroendocrine neoplasms: An analysis of 3523 patients in the SEER database.
Cao LL; Lu J; Lin JX; Zheng CH; Li P; Xie JW; Wang JB; Chen QY; Lin M; Tu RH; Huang CM
Eur J Surg Oncol; 2018 Oct; 44(10):1628-1633. PubMed ID: 29983275
[TBL] [Abstract][Full Text] [Related]
3. Pancreatic neuroendocrine tumours: Grade is superior to T, N, or M status in predicting outcome and selecting patients for chemotherapy:A retrospective cohort study in the SEER database.
Zhai H; Li D; Feng Q; Qian X; Li L; Yao J
Int J Surg; 2019 Jun; 66():103-109. PubMed ID: 30872175
[TBL] [Abstract][Full Text] [Related]
4. Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.
Dasari A; Shen C; Halperin D; Zhao B; Zhou S; Xu Y; Shih T; Yao JC
JAMA Oncol; 2017 Oct; 3(10):1335-1342. PubMed ID: 28448665
[TBL] [Abstract][Full Text] [Related]
5. Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival.
Halfdanarson TR; Rabe KG; Rubin J; Petersen GM
Ann Oncol; 2008 Oct; 19(10):1727-33. PubMed ID: 18515795
[TBL] [Abstract][Full Text] [Related]
6. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
[TBL] [Abstract][Full Text] [Related]
7. Epidemiology and classification of gastroenteropancreatic neuroendocrine neoplasms using current coding criteria.
Sandvik OM; Søreide K; Gudlaugsson E; Kvaløy JT; Søreide JA
Br J Surg; 2016 Feb; 103(3):226-32. PubMed ID: 26511392
[TBL] [Abstract][Full Text] [Related]
8. Survival of patients with neuroendocrine carcinoma of the colon and rectum: a population-based analysis.
Shafqat H; Ali S; Salhab M; Olszewski AJ
Dis Colon Rectum; 2015 Mar; 58(3):294-303. PubMed ID: 25664707
[TBL] [Abstract][Full Text] [Related]
9. Incidence and prevalence of neuroendocrine tumors of the lung: analysis of a US commercial insurance claims database.
Broder MS; Cai B; Chang E; Neary MP
BMC Pulm Med; 2018 Aug; 18(1):135. PubMed ID: 30103725
[TBL] [Abstract][Full Text] [Related]
10. Gastric Neuroendocrine Tumors (G-Nets): Incidence, Prognosis and Recent Trend Toward Improved Survival.
Yang Z; Wang W; Lu J; Pan G; Pan Z; Chen Q; Liu W; Zhao Y
Cell Physiol Biochem; 2018; 45(1):389-396. PubMed ID: 29402806
[TBL] [Abstract][Full Text] [Related]
11. Epidemiologic trends in neuroendocrine tumors: An examination of incidence rates and survival of specific patient subgroups over the past 20 years.
Sackstein PE; O'Neil DS; Neugut AI; Chabot J; Fojo T
Semin Oncol; 2018 Aug; 45(4):249-258. PubMed ID: 30348533
[TBL] [Abstract][Full Text] [Related]
12. Best prognostic factor of neuroendocrine tumors: Grade or Stage? A multidisciplinary single-center study.
Özaslan E; Bayram F; Karaca H; Gürsoy Ş; Öztürk F; Sözüer E; Abdurrezzak Ü; Yurci A; Can Sezgin G; Yıldırım A; Başpınar O; Kula M; Özkan M
Turk J Gastroenterol; 2016 Nov; 27(6):509-514. PubMed ID: 27852541
[TBL] [Abstract][Full Text] [Related]
13. Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: experience of two decades of cancer registry.
Korse CM; Taal BG; van Velthuysen ML; Visser O
Eur J Cancer; 2013 May; 49(8):1975-83. PubMed ID: 23352435
[TBL] [Abstract][Full Text] [Related]
14. Rare tumors of the colon and rectum: a national review.
Kang H; O'Connell JB; Leonardi MJ; Maggard MA; McGory ML; Ko CY
Int J Colorectal Dis; 2007 Feb; 22(2):183-9. PubMed ID: 16845516
[TBL] [Abstract][Full Text] [Related]
15. A Retrospective Cohort Study of Histology-Proven Neuroendocrine Neoplasms in the Italian Area of Udine.
Valent F; Tullio A; Kara E; Cipri C; Sciannimanico SM; Vescini F; Grimaldi F
Endocr Metab Immune Disord Drug Targets; 2021; 21(3):448-457. PubMed ID: 32660412
[TBL] [Abstract][Full Text] [Related]
16. Population-level analysis of pancreatic neuroendocrine tumors 2 cm or less in size.
Kuo EJ; Salem RR
Ann Surg Oncol; 2013 Sep; 20(9):2815-21. PubMed ID: 23771245
[TBL] [Abstract][Full Text] [Related]
17. Trends in the incidence of thymoma, thymic carcinoma, and thymic neuroendocrine tumor in the United States.
Hsu CH; Chan JK; Yin CH; Lee CC; Chern CU; Liao CI
PLoS One; 2019; 14(12):e0227197. PubMed ID: 31891634
[TBL] [Abstract][Full Text] [Related]
18. Incidence and clinical characteristics of gastroenteropancreatic neuroendocrine tumor in Korea: a single-center experience.
Lim CH; Lee IS; Jun BY; Kim JS; Cho YK; Park JM; Roh SY; Lee MA; Kim SW; Choi MG
Korean J Intern Med; 2017 May; 32(3):452-458. PubMed ID: 28490723
[TBL] [Abstract][Full Text] [Related]
19. Using Data on Tumor Grade in Cancer Registries to Enhance Surveillance of Oropharyngeal Cancers in Relation to the Human Papillomavirus Epidemic.
Polednak AP
J Registry Manag; 2016; 43(1):29-35. PubMed ID: 27195996
[TBL] [Abstract][Full Text] [Related]
20. Epidemiologic trends and prognostic risk factors of patients with pancreatic neuroendocrine neoplasms in the US: an updated population-based study.
Lu L; Shang Y; Mullins CS; Zhang X; Linnebacher M
Future Oncol; 2021 Feb; 17(5):549-563. PubMed ID: 33401958
[No Abstract] [Full Text] [Related]
[Next] [New Search]
